MAPK14 and esophageal squamous cell carcinoma: When we applied the drugs that showed excellent binding ability with MAPK14, to inhibit the activity of MAPK14, it would also affect the ubiquitination and deubiquitylation pathway and then make the tumor cell more sensitive to the drugs, suggesting that they may serve as anti-ESCC drugs targeting MAPK14.